AP2498A - Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol - Google Patents
Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanolInfo
- Publication number
- AP2498A AP2498A AP2009004870A AP2009004870A AP2498A AP 2498 A AP2498 A AP 2498A AP 2009004870 A AP2009004870 A AP 2009004870A AP 2009004870 A AP2009004870 A AP 2009004870A AP 2498 A AP2498 A AP 2498A
- Authority
- AP
- ARIPO
- Prior art keywords
- alpha
- beta
- quinolineethanol
- naphthalenyl
- dimethylamino
- Prior art date
Links
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06125443 | 2006-12-05 | ||
PCT/EP2007/063186 WO2008068231A1 (en) | 2006-12-05 | 2007-12-03 | Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2009004870A0 AP2009004870A0 (en) | 2009-06-30 |
AP2498A true AP2498A (en) | 2012-10-19 |
Family
ID=37983588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2009004870A AP2498A (en) | 2006-12-05 | 2007-12-03 | Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Country Status (34)
Country | Link |
---|---|
US (1) | US8546428B2 (da) |
EP (1) | EP2086940B1 (da) |
JP (2) | JP2010511663A (da) |
KR (1) | KR101514700B1 (da) |
CN (2) | CN105012303A (da) |
AP (1) | AP2498A (da) |
AR (1) | AR064149A1 (da) |
AU (1) | AU2007328945B2 (da) |
BR (1) | BRPI0719693A2 (da) |
CA (1) | CA2668512C (da) |
CL (1) | CL2007003472A1 (da) |
CY (1) | CY1113594T1 (da) |
DK (1) | DK2086940T3 (da) |
EA (1) | EA017091B9 (da) |
ES (1) | ES2387923T3 (da) |
HK (1) | HK1214513A1 (da) |
HR (1) | HRP20120639T1 (da) |
IL (1) | IL199077A (da) |
JO (1) | JO2973B1 (da) |
ME (1) | ME01456B (da) |
MX (1) | MX2009005909A (da) |
MY (1) | MY148844A (da) |
NO (1) | NO342773B1 (da) |
NZ (1) | NZ576485A (da) |
PE (1) | PE20081350A1 (da) |
PL (1) | PL2086940T3 (da) |
PT (1) | PT2086940E (da) |
RS (1) | RS52408B (da) |
SI (1) | SI2086940T1 (da) |
TW (1) | TWI417098B (da) |
UA (1) | UA97813C2 (da) |
UY (1) | UY30762A1 (da) |
WO (1) | WO2008068231A1 (da) |
ZA (1) | ZA200903907B (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
CZ2014708A3 (cs) | 2014-10-16 | 2016-04-27 | Zentiva, K.S. | Soli Bedaquilinu |
EP3250182B1 (en) * | 2015-01-27 | 2023-04-26 | Janssen Pharmaceutica NV | Dispersible compositions |
CN106279017A (zh) * | 2015-05-21 | 2017-01-04 | 重庆圣华曦药业股份有限公司 | 贝达喹啉晶型、组合物及其制备方法 |
CZ2015391A3 (cs) | 2015-06-09 | 2016-12-21 | Zentiva, K.S. | Sůl bedaquilinu s kyselinou citronovou |
KR102106318B1 (ko) * | 2015-10-20 | 2020-05-06 | 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 | 베다퀼린 푸마레이트의 결정형 및 그의 제조방법 |
LT3487851T (lt) * | 2016-07-20 | 2021-12-27 | Novartis Ag | Aminopiridino dariniai ir jų naudojimas kaip selektyvių alk-2 inhibitorių |
CN106316943A (zh) * | 2016-07-27 | 2017-01-11 | 重庆华邦制药有限公司 | 富马酸贝达喹啉晶型化合物的精制方法 |
CN113271930A (zh) | 2019-01-09 | 2021-08-17 | 詹森药业有限公司 | 治疗非结核分枝杆菌疾病的组合 |
WO2020161743A1 (en) * | 2019-02-08 | 2020-08-13 | Mylan Laboratories Limited | Process for the preparation of bedaquiline fumarate |
KR102303635B1 (ko) * | 2020-07-01 | 2021-09-17 | 동아에스티 주식회사 | (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법 |
CN111888477B (zh) * | 2020-09-15 | 2023-03-07 | 北京福元医药股份有限公司 | 一种贝达喹啉药物制剂 |
EP4243800A1 (en) | 2020-11-12 | 2023-09-20 | JANSSEN Pharmaceutica NV | Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases |
US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
WO2023232838A1 (en) | 2022-05-31 | 2023-12-07 | Janssen Pharmaceutica Nv | Bedaquiline for use in the treatment of leprosy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004011436A1 (en) * | 2002-07-25 | 2004-02-05 | Janssen Pharmaceutica N.V. | Quinoline derivatives and their use as mycobacterial inhibitors |
WO2005117875A1 (en) * | 2004-05-28 | 2005-12-15 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3237575A1 (de) * | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
GB8824392D0 (en) * | 1988-10-18 | 1988-11-23 | Ciba Geigy Ag | Dispersible formulation |
TW355683B (en) * | 1994-02-17 | 1999-04-11 | Janssen Pharmaceutica Nv | Composition containing micronized nebivolol |
JP2001503411A (ja) | 1996-10-28 | 2001-03-13 | ディパートメント オブ ジ アーミー,ユー.エス.ガバメント | 抗生物質耐性感染症の処置のための化合物、組成物および方法 |
CA2219377A1 (en) * | 1996-10-30 | 1998-04-30 | Eli Lilly And Company | Improvements in or relating to the prophylaxis of breast cancer |
US6819464B2 (en) * | 2002-06-19 | 2004-11-16 | Seiko Epson Corporation | Optical modulator, optical device and projector |
WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
WO2006024667A1 (en) * | 2004-09-02 | 2006-03-09 | Janssen Pharmaceutica N.V. | Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile |
JP2006182755A (ja) * | 2004-12-24 | 2006-07-13 | Janssen Pharmaceut Nv | 潜伏性結核の処置 |
-
2007
- 2007-03-12 UA UAA200904218A patent/UA97813C2/uk unknown
- 2007-12-02 JO JO2007511A patent/JO2973B1/en active
- 2007-12-03 MY MYPI20092284A patent/MY148844A/en unknown
- 2007-12-03 ME MEP-2012-95A patent/ME01456B/me unknown
- 2007-12-03 PL PL07847697T patent/PL2086940T3/pl unknown
- 2007-12-03 KR KR1020097011043A patent/KR101514700B1/ko active IP Right Grant
- 2007-12-03 BR BRPI0719693-8A2A patent/BRPI0719693A2/pt not_active Application Discontinuation
- 2007-12-03 EA EA200970532A patent/EA017091B9/ru active Protection Beyond IP Right Term
- 2007-12-03 AP AP2009004870A patent/AP2498A/xx active
- 2007-12-03 JP JP2009539724A patent/JP2010511663A/ja active Pending
- 2007-12-03 NZ NZ576485A patent/NZ576485A/en unknown
- 2007-12-03 CN CN201510368829.1A patent/CN105012303A/zh active Pending
- 2007-12-03 CN CNA2007800448088A patent/CN101547904A/zh active Pending
- 2007-12-03 PT PT07847697T patent/PT2086940E/pt unknown
- 2007-12-03 CA CA2668512A patent/CA2668512C/en active Active
- 2007-12-03 WO PCT/EP2007/063186 patent/WO2008068231A1/en active Application Filing
- 2007-12-03 CL CL200703472A patent/CL2007003472A1/es unknown
- 2007-12-03 RS RS20120336A patent/RS52408B/en unknown
- 2007-12-03 SI SI200730984T patent/SI2086940T1/sl unknown
- 2007-12-03 MX MX2009005909A patent/MX2009005909A/es active IP Right Grant
- 2007-12-03 US US12/515,986 patent/US8546428B2/en active Active
- 2007-12-03 EP EP07847697A patent/EP2086940B1/en active Active
- 2007-12-03 ES ES07847697T patent/ES2387923T3/es active Active
- 2007-12-03 DK DK07847697.5T patent/DK2086940T3/da active
- 2007-12-03 AU AU2007328945A patent/AU2007328945B2/en active Active
- 2007-12-04 TW TW096146000A patent/TWI417098B/zh active
- 2007-12-05 PE PE2007001719A patent/PE20081350A1/es active IP Right Grant
- 2007-12-05 AR ARP070105442A patent/AR064149A1/es not_active Application Discontinuation
- 2007-12-05 UY UY30762A patent/UY30762A1/es active IP Right Grant
-
2009
- 2009-06-02 IL IL199077A patent/IL199077A/en active IP Right Grant
- 2009-06-04 ZA ZA2009/03907A patent/ZA200903907B/en unknown
- 2009-07-06 NO NO20092535A patent/NO342773B1/no unknown
-
2012
- 2012-08-06 HR HRP20120639TT patent/HRP20120639T1/hr unknown
- 2012-08-13 CY CY20121100734T patent/CY1113594T1/el unknown
-
2014
- 2014-09-19 JP JP2014191134A patent/JP5894239B2/ja active Active
-
2016
- 2016-03-04 HK HK16102481.4A patent/HK1214513A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004011436A1 (en) * | 2002-07-25 | 2004-02-05 | Janssen Pharmaceutica N.V. | Quinoline derivatives and their use as mycobacterial inhibitors |
WO2005117875A1 (en) * | 2004-05-28 | 2005-12-15 | Janssen Pharmaceutica N.V. | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases |
Non-Patent Citations (1)
Title |
---|
DATABASE REGISTRY, 14 May 2005 (2005-05-14), XP002433954, accession no. 845533-86-0, abstract * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP2498A (en) | Fumarate salt of (ALPHA S, BETA R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol | |
EP1986699A4 (en) | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | |
EP2046259A4 (en) | PATIENTS LIEGE | |
GB0610680D0 (en) | Therapeutic compounds | |
IL193678A0 (en) | Therapeutic compounds | |
GB0603041D0 (en) | Therapeutic compounds | |
IL193102A0 (en) | Deuterated catecholamine derivatives and medicaments comprising said compounds | |
HK1203925A1 (en) | Therapeutic compounds | |
GB0606663D0 (en) | Therapeutic compounds | |
GB0615809D0 (en) | Therapeutic compounds | |
GB0612971D0 (en) | Therapeutic compounds | |
GB0625349D0 (en) | Therapeutic compounds | |
EP2079704A4 (en) | THERAPEUTIC COMPOUNDS | |
GB0625345D0 (en) | Therapeutic compounds | |
GB0605573D0 (en) | Therapeutic Compounds | |
GB0603455D0 (en) | Therapeutic compounds | |
IL205752A0 (en) | Octahydroquinolizines for antidiabetic treatment | |
IL188897A0 (en) | 3-(2-(dimethylamino)methyl(cyclohex | |
GB0608269D0 (en) | Therapeutic compounds | |
GB2439923B (en) | Therapeutic compounds | |
ITMI20060760A1 (it) | Procedimento per il trattamento di tessuti | |
AU312984S (en) | Headgear for patient interface | |
AU312983S (en) | Headgear for patient interface | |
GB0611498D0 (en) | Therapeutic compounds | |
GB0615907D0 (en) | Therapeutic Compounds |